PBM Part D Rebate, Price Concession Disclosure Obligations Clarified In CMS Proposal
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS is aiming for greater transparency in Part D rebates and price concessions.
You may also be interested in...
Paying for Protection: Medicare Rebates May Make Protected Classes Less Safe for Sponsors
Democrats failed in their first attempt to impose price controls in Medicare Part D. But, led by California Rep. Waxman, they may have found a new approach that seems less threatening than price negotiations-rebates for products used by dual eligible patients. And the drugs most likely to be affected are in Part D's six protected classes.
Rebates Redux: Medicare Drug Rebates Next?
Drug prices have lost their headline appeal. That has got to be a relief to pharma execs who have pipeline problems and patent expirations to deal with and don't need to be worried about bad publicity egging on Congress to price-control schemes. But there are new threats to drug prices brewing - and one of them is industry's old nemesis: government rebates.
Merck Suit Against Medicare: Constitutional Arguments Are Scathing, But Are They Persuasive?
A suit designed to test the limits of the protections against judicial review that are embedded in the IRA could have more traction, some legal scholars suggest.